Tirzepatide cuts liver fat in mice via macrophage Dectin-1 pathway
Mice on a high-fat, high-fructose diet got 10 nmol/kg subcutaneously every three days for seven weeks, with reduced hepatic macrophage accumulation and Syk/p65 phosphorylation.
PR
By Priya Raman · Science Reporter
Oct 7 20:00 ETSource: European journal of pharmacology
The wire
- 01In European Journal of Pharmacology, tirzepatide improved steatosis, liver injury and inflammation in HFHFD-fed C57BL/6J mice, reversing diet-induced Clec7a upregulation and suppressing Dectin-1/Syk/NF-κB signaling.
- 02Adds a candidate mechanism beyond weight and glucose for incretin effects in MASLD, relevant to clinicians already fielding questions about tirzepatide and fatty liver disease.
- 03Findings are from mice plus PA-stimulated RAW264.7 and HepG2 cell models; Dectin-1 knockdown blunted the added tirzepatide effect, and no human data are presented.
From the source
Read at pubmed.ncbi.nlm.nih.govTirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling
European journal of pharmacology · 2026 Oct 8 · He Y, Ma T, Xing H et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42849688/
